ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "TNF-blocking Antibody"

  • Abstract Number: 1439 • ACR Convergence 2024

    Risk of Hip and Spine Fractures in Axial Spondyloarthritis Is Associated with Treatment Class

    Devin Driscoll1, Navya George2, S. Reza Jafarzadeh3, Christine Peloquin3, Jean Liew3 and Maureen Dubreuil4, 1Boston Medical Center, Boston, MA, 2Boston University Medical Center Internal Medicine Residency Program, Boston, MA, 3Boston University Chobanian & Avedisian School of Medicine, Boston, MA, 4Section of Rheumatology, Boston University School of Medicine, Boston, MA

    Background/Purpose: Individuals with axial spondyloarthritis (axSpA) have a risk of fracture that is nearly double that of the general population, possibly related to chronic inflammation.…
  • Abstract Number: 1647 • ACR Convergence 2024

    Improved Fertility in Women with Rheumatoid Arthritis and a Wish to Conceive When Treated According to a Treat-to-target Approach Aimed at Remission

    Cornelia H. Quaack1, Esther Röder1, Hetty M. Wintjes1, Anneke J. van Steensel-Boon1, Annemarie G.M.G.J. Mulders2, Laura C.J. Kranenburg-van Koppen1 and radboud J.e.m. Dolhain1, 1Department of Rheumatology, Erasmus University Medical Center, Rotterdam, Netherlands, 2Department of Obstetrics and Gynaecology, Erasmus Medical Center, Rotterdam, Netherlands

    Background/Purpose: Time to conception, known as time to pregnancy (TTP), is prolonged in women diagnosed with RA. High rates of infertility, defined as the inability…
  • Abstract Number: 2269 • ACR Convergence 2024

    Adalimumab Dose Reduction Using Therapeutic Drug Monitoring to Manage Low Disease Activity in Rheumatoid Arthritis: A Single-Blind, Non-Inferiority, Randomized Clinical Trial

    Sadaf Atiqi1, Maike Wientjes2, Maureen Leeuw3, Laura Boekel4, Femke Hooijberg1, Floris Loeff5, Charlotte Krieckaert1, Annick De Vries5, Michael Nurmohamed6, Theo Rispens5, Maarten Boers7, Bart van den Bemt8, Alfons den Broeder2 and Gertjan Wolbink9, 1Reade, Amsterdam, Netherlands, 2Sint Maartenskliniek, Ubbergen, Netherlands, 3Reade, Zeist, Netherlands, 4Vrije Universiteit Amsterdam, Amsterdam, Netherlands, 5Sanquin Diagnostic Services, Amsterdam, Netherlands, 6Reade and Amsterdam UMC, Kortenhoef, Netherlands, 7Amsterdam UMC, Vrije Universiteit, Amersfoort, Netherlands, 8Sint Maartenskliniek / Radboudumc, Ubbergen, Netherlands, 9Reade and Sanquin Diagnostic Services, Amsterdam, Netherlands

    Background/Purpose: The latest European and American recommendations support tapering of biological DMARDs (bDMARDs) in patients with persistent remission or low disease activity. Most clinicians use…
  • Abstract Number: 2286 • ACR Convergence 2024

    Certolizumab Inhibits Radiographic Progression Even in RA Patients with High Rheumatoid Factor Levels: A Pooled, Post-Hoc Analysis of Two Phase 3 Trials

    Josef Smolen1, Gerd Burmester2, Yoshiya Tanaka3, Tsutomu Takeuchi4, Jeffrey Curtis5, Ted Mikuls6, Clementina López Medina7, Peter C. Taylor8, Nicola Tilt9, Bernard Lauwerys10, Baran Ufuktepe11 and Thomas Huizinga12, 1Medical University of Vienna, Vienna, Austria, 2Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 3Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 4Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, 5The University of Alabama at Birmingham, Birmingham, AL, 6University of Nebraska Medical Center, Omaha, NE, 7Reina Sofia University Hospital, Cordoba, Spain, 8University of Oxford, Oxford, United Kingdom, 9UCB Pharma, Slough, United Kingdom, 10UCB Pharma, Brussels, Belgium, 11UCB Pharma, Istanbul, Turkey, 12Department of Rheumatology, Leiden University, Leiden, Netherlands

    Background/Purpose: In patients (pts) with rheumatoid arthritis (RA), including those treated with disease-modifying antirheumatic drugs, high rheumatoid factor (RF) levels are a poor prognostic factor,…
  • Abstract Number: 2358 • ACR Convergence 2024

    Integration of Single-cell Multi-omics Profiling for Investigating Treatment Response to Tumor Necrosis Factor Alpha Inhibitors in Patients with Axial Spondyloarthritis

    Seulkee Lee1, Jae Soon Park2, Elizaveta Ignatova2, Seonyoung Kang3, Hyungjin Kim1, Jaejoon Lee1, Jung Kyoon Choi2 and Hoon-Suk Cha1, 1Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Republic of Korea, 2KAIST, Daejeon, Republic of Korea, 3Samsung Medical Center, Gangnam-gu, Seoul, South Korea

    Background/Purpose: In cases where patients continue to experience active symptoms despite receiving maximum doses of nonsteroidal anti-inflammatory drug therapy in patients with axial spondyloarthritis (axSpA),…
  • Abstract Number: 2674 • ACR Convergence 2024

    Real-World Analysis of Initial Clinical Response and Future Outcomes Among Patients with Rheumatoid Arthritis Initiating and Remaining on a 1st-Line Tumor Necrosis Factor Inhibitor in the United States

    christina Charles-Schoeman1, Patrick Zueger2, Erin Blondell2, Siran Fang2, Yi Peng2, Manish Jain3 and John Tesser4, 1UCLA Medical Center, Santa Monica, CA, 2AbbVie Inc, North Chicago, IL, 3Endeavor Health Swedish Hospital and Captain James A, Chicago, IL, 4Arizona Arthritis and Rheumatology Associates, P.C., Phoenix, AZ

    Background/Purpose: For patients with rheumatoid arthritis (RA), current ACR guidelines recommend evaluating treatment response within 3 months of initiating a new therapy. In patients who…
  • Abstract Number: 0465 • ACR Convergence 2024

    Therapeutic Drug Monitoring of the Adalimumab Biosimilar (AMJEVITA™, Adalimumab-atto) Using Originator Adalimumab and Anti-Adalimumab Antibody Assays

    Monique Bastidas1, Lythou Yeo1, Susie Magpantay1, Judah Scott1, Mike Zikry1, Wayne Galdamez1, Jane Yang2 and Kelly Chun1, 1Labcorp, Calabasas, CA, 2LabCorp, Weston, MA

    Background/Purpose: Treatment of RA with biologic TNF inhibitors is effective in reducing disease activity and improving radiographic progression outcomes. Therapeutic drug monitoring (TDM) of adalimumab…
  • Abstract Number: 0499 • ACR Convergence 2024

    PD-1hiCXCR5-CD4+T Peripheral Helper Cells Enrich in Rheumatoid Arthritis and Predict Clinical Response to Anti-TNF Treatment

    Wanki Ho1, Huaqun Zhu1, Hua Ye1, Dongdong Fu2 and Xi Xu1, 1Peking University People's Hospital, Beijing, China, 2Xinxiang Central Hospital, Xinxiang, Henan, China (People's Republic)

    Background/Purpose: PD-1hiCXCR5-CD4+T peripheral helper cells (Tph) are newly identified pathogenic CD4+T helper cells and participate in rheumatoid arthritis (RA) pathogenesis. However, the clinical significance of…
  • Abstract Number: 0511 • ACR Convergence 2024

    Do High Rheumatoid Factor Levels Impact Response to Certolizumab Pegol in Patients with Inadequately Controlled Rheumatoid Arthritis? A Post Hoc Analysis of a Phase 3b Trial

    Josef Smolen1, Ted Mikuls2, James Galloway3, Ulf Müller-Ladner4, Jeffrey Curtis5, Motomu Hashimoto6, Tsutomu Takeuchi7, Ernest Choy8, Yoshiya Tanaka9, Carlos Cara10, Bernard Lauwerys11, Nicola Tilt12, Baran Ufuktepe13 and Peter C. Taylor14, 1Medical University of Vienna, Vienna, Austria, 2University of Nebraska Medical Center, Omaha, NE, 3Centre for Rheumatic Diseases, King's College London, London, United Kingdom, 4Justus-Liebig University Giessen, Bad Nauheim, Germany, 5University of Alabama at Birmingham, Hoover, AL, 6Osaka Metropolitan University, Osaka, Japan, 7Department of Internal Medicine, Keio University, Tokyo, Tokyo, Japan, 8Cardiff University School of Medicine, Cardiff, United Kingdom, 9Department of Internal Medicine, University of Occupational and Environmental Health, Kitakyushu, Fukuoka, Japan, 10UCB Pharma, Madrid, Spain, 11UCB Pharma, Brussels, Belgium, 12UCB Pharma, Slough, United Kingdom, 13UCB Pharma, Istanbul, Turkey, 14University of Oxford, Oxford, United Kingdom

    Background/Purpose: In pts with RA, high RF levels are associated with poor prognosis, higher disease activity, and decreased response to monoclonal antibodies targeting tumor necrosis…
  • Abstract Number: 0871 • ACR Convergence 2024

    Disease-associated Central Nervous System Activation Predicts Good Clinical Response to Tumor Necrosis Factor Inhibition in Rheumatoid Arthritis Patients – “The PreCePRA Study”

    Juergen Rech1, Prof. Dr. Andreas Hess2, Koray Tascilar1, Dr. Hannah Schenker3, verena schönau1, Marina Sergeeva2, Jutta Prade2, Silke Kreitz2, Mageshva Sulvakumar2, Laura Konerth2, Sandra Strobelt2, Matthias Englbrecht4, Prof. Dr. Dr. Axel Hueber5, Eugen Feist6, Prof. Dr. Mario Zaiss1, Gerd Burmester7, Frank Behrens8, Dr. Michaela Koehm9, Prof. Dr. Christoph Baerwald10, Dr. Stephanie Finzel11, Dr. Arnd Kleyer12, Prof. Dr. Reinhard Voll11, Dr. Julie Roesch13, Prof. Dr. Arnd Doerfler13, Prof. Dr. Nemanja Damjanov14, Prof. José António P. Da Silva15 and Georg Schett16, 1Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 2Institute for Experimental Pharmacology FAU Erlangen-Nürnberg, Erlangen, Germany, 3Department of Internal Medicine 3 - Rheumatology and Immunology, Department of Internal Medicine 1 - Gastroenterology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany, Erlangen, Germany, 4Freelance Healthcare Data Scientist, Eckental, 5Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, + Rheumatologie, Klinik für Innere Medizin 5, Klinikum Nürnberg Nord, Prof.-Ernst-Nathan-Str. 1, 90419, Nürnberg, Deutschland, Erlangen, Germany, 6Department of Rheumatology, Helios Clinic Vogelsang-Gommern, cooperation partner of the Otto von Guericke University Magdeburg, Gommern, Germany, 7Department of Rheumatology and Clinical Immunology, Charité – Universitätsmedizin Berlin, Berlin, Germany, 8University Hospital Goethe University Frankfurt and Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Frankfurt, Germany, 9Goethe-University & Fraunhofer ITMP, Frankfurt, Germany, 10Medizinische Klinik III - Bereich Rheumatologie, Liebigstraße 20, 04103 Leipzig, Leipzig, Germany, 11Universitätsklinikum Freiburg, Klinik für Rheumatologie und Klinische Immunologie, Hugstetterstraße 55, 79106 Freiburg, Freiburg, Germany, 12Department of Internal Medicine 3 - Rheumatology and Immunology, Friedrich-Alexander University (FAU) Erlangen-Nürnberg and Universitätsklinikum Erlangen, Erlangen, Germany, Deutsches Zentrum für Immuntherapie (DZI), Friedrich Alexander University Erlangen-Nuremberg and Universitätsklinikum Erlangen, Erlangen, Germany; Charité - Universitätsmedizin Berlin Med. Klinik mit Schwerpunkt Rheumatologie und Klinische Immunologie Berlin, Erlangen, Germany, 13Department of Neuroradiology, Friedrich - Alexander - Universitaet Erlangen - Nuernberg and Universitaetsklinikum Erlangen , Erlangen , Germany, Erlangen, Germany, 14Belgrade University School of Medicine, Institute Institute of Rheumatology, Belgrade, Belgrade, Serbia, 15Head of Department Reumatologia. Hospitais da Universidade (SRHUC), Coimbra, Portugal, 16Friedrich-Alexander-Universität Erlangen-Nürnberg, Erlangen, Germany

    Background/Purpose: Rheumatoid arthritis (RA) is an chronic inflammatory disease that is frequently treated with tumor necrosis factor inhibitors (TNFi). Little is known about predictors of…
  • Abstract Number: 0989 • ACR Convergence 2024

    Malignancy Risk Between JAK Inhibitors and Anti-TNF Therapy Across Disease Indications: A Bayesian Network Meta-analysis

    Mark Gibson1, Benjamin Zuckerman2, Maryam Adas1, Mark Russell3, Katie Bechman1 and James Galloway4, 1King's College London, London, United Kingdom, 2King's College London, London, England, United Kingdom, 3King's College London, London, United Kingdom, 4Centre for Rheumatic Diseases, King's College London, London, United Kingdom

    Background/Purpose: To estimate the relative risk of malignancy between Janus kinase inhibitors (JAKi), tumour necrosis factor-α inhibitors (TNFi) and placebo in individuals with immune-mediated inflammatory…
  • Abstract Number: 1119 • ACR Convergence 2024

    Treatment Outcomes of TNF-α Inhibitors in Cardiac Sarcoidosis

    Kailey Singh1, Harrison Zucker1, Alice Kwon2, Audrey Liu3, Josephine Rini1, Elena Katzap4, Sonali Narain5 and Galina Marder6, 1Northwell Health at Northshore/Long Island Jewish, Manhasset, 2Northwell Health at Northshore/Long Island Jewish, Bayside, NY, 3Loma Linda University, Loma Linda, CA, 4Northwell Health, Great NY, NY, 5Northwell Health, Great Neck, NY, 6Donald and Barbara Zucker School of Medicine at Hofstra/ Northwell, Great Neck, NY

    Background/Purpose: Management of cardiac sarcoidosis remains controversial. Our study aimed to describe our experience using tumor necrosis factor-α-inhibitors (aTNF) in cardiac sarcoidosis treatment.Methods: This is a…
  • Abstract Number: 1348 • ACR Convergence 2024

    Analysis of Body Composition in Patients with Moderate-Severe Rheumatoid Arthritis Treated with Anti-TNF Drugs

    Aimara García-Studer1, Fernando Ortiz-Márquez1, Paula Borregón-Garrido1, Arkaitz Mucientes-Ruiz1, Sara Manrique-Arija1 and Natalia Mena Vázquez2, 1Biomedical Research Institute of Malaga (IBIMA)-Bionand Platform, Department of Rheumatology, Regional University Hospital of Malaga, Malaga, Spain, 2IBIMA, Málaga, Andalucia, Spain

    Background/Purpose: Previous studies have described alterations in fat and lean mass in patients with RA, but the effect of treatments on body composition remains unclear.…
  • Abstract Number: 1383 • ACR Convergence 2024

    Proteomics and Machine Learning Accurately Predict Clinical Response to Etanercept Therapy in Patients with Rheumatoid Arthritis

    Huaqun Zhu1, Gong cheng1, yingni Li1, Yun Li1, Feng Sun1, Hongyan Wang1, Qinqin li2, Zhilun Li3, Ru Li4 and Zhanguo Li5, 1Peking University People's Hospital, Beijing, China, 2Sansheng Guojian Pharmaceutical (Shanghai) Company, Shanghai, China (People's Republic), 3Sansheng Guojian Pharmaceutical (Shanghai) Company, Shanghai, 4Department of Rheumatology and Immunology, Peking University People’s Hospital, Beijing, China, 5People’s Hospital Peking University Health Sciences Centre, Beijing, China

    Background/Purpose: Our study aimed to use machine-learning approaches to characterize the proteomics profiles of patients who were inadequate responders to Etanercept (ETN-IRs) and develop an…
  • Abstract Number: 1135 • ACR Convergence 2023

    The Prescribing Patterns and Role of TNF-α Inhibitors in Treatment of Cardiac Sarcoidosis Patients

    Alice Kwon1, Audrey Liu1, Sonali Narain2, Elena Katzap3 and Galina Marder2, 1Northwell Health, Manhasset, NY, 2Donald and Barbara Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, 3Northwell Health, Great NY, NY

    Background/Purpose: Cardiac sarcoidosis is one of the most common causes of mortality from sarcoidosis. In this retrospective study, we describe prescribing patterns and compare outcomes between patients treated with conventional immunosuppressive therapies…
  • 1
  • 2
  • 3
  • …
  • 5
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology